[皮下免疫疗法对儿童哮喘和鼻炎肺功能及症状的分析]
[An analysis of the subcutaneous immunotherapy on the pulmonary function and symptoms of asthma and rhinitis in children].
作者信息
Wu S J, Chen S, Chen B, Wang L, Zeng X
机构信息
Asthmatic Children Prevention and Specific Immunotherapy Center, Peoples' Hospital of Hainan Province, Haikou, 570311, China.
出版信息
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Sep 5;31(17):1352-1355. doi: 10.13201/j.issn.1001-1781.2017.17.014.
To evaluate the effect of subcutaneous immunotherapy on allergic asthma and rhinitis in children.A prospective study was adopted to analysis 3 years SCIT treatment of 144 cases of children with allergic asthma and rhinitis. Before and after SCIT treatment for 1 year, 2 and 3 years, FEV1, daytime and night symptoms of asthma and rhinitis were evaluated.After 3 years of SCIT treatment, the FEV1 had significantly increased (= 243.05, < 0.01), and with the duration of the treatment was further improvement (< 0.01). Compared with the baseline, treatment 1 year in daytime, nighttime symptoms scores of asthma and nighttime symptoms scores of rhinitis had significantly reduced (< 0.01). All symptoms were reduced further by 2 years of treatment (< 0.01) compared with 1 year. Compared with the 2 years of treatment, daytime symptoms of asthma and rhinitis of 3 years SCIT treatment was improved significantly (< 0.05).Subcutaneous immunotherapy with 3 years in children allergic with asthma and rhinitis can play a significant effect.
评估皮下免疫疗法对儿童过敏性哮喘和鼻炎的疗效。采用前瞻性研究分析144例儿童过敏性哮喘和鼻炎患者3年的皮下免疫疗法治疗情况。在皮下免疫疗法治疗1年、2年和3年后，评估第一秒用力呼气容积（FEV1）、哮喘和鼻炎的日间及夜间症状。皮下免疫疗法治疗3年后，FEV1显著增加（=243.05，<0.01），且随着治疗时间延长进一步改善（<0.01）。与基线相比，治疗1年后哮喘的日间、夜间症状评分及鼻炎的夜间症状评分显著降低（<0.01）。与1年治疗相比，2年治疗后所有症状进一步减轻（<0.01）。与2年治疗相比，3年皮下免疫疗法治疗哮喘和鼻炎的日间症状显著改善（<0.05）。对患有哮喘和鼻炎的儿童进行3年皮下免疫疗法可发挥显著效果。
Zotero 插件